Company profile
Theralase Technologies Inc.
OTC: TLTFF · Healthcare · Medical - Devices
Canadian filerHQ Toronto, ONReports USD
#922 of 1,418 Healthcare companies by revenue27th-percentile growth
EA Score
37DFH 33DQ —GM 42SS 52
v0.1 · 45/100 weight · provisional
↑ growth stability, listing tenure · ↓ return on equity, Piotroski F
Methodology →Revenue TTM
$620.6k
Rev growth YoY (TTM)
-9.4%
Net income (FY)
-$2.9M
Employees
14
as of 2026-08-19
Market cap
$38.4M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$584.1k816.5k CAD2025
Net income-$2.9M-4.1M CAD2025
Operating income-$3.0M-4.2M CAD2025
Total assets$2.5M3.5M CAD2025
Liabilities$1.3M1.7M CAD2025
Equity$1.3M1.8M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Theralase Technologies Inc.’s revenue?
Theralase Technologies Inc. booked $584.1k in FY2025 revenue, contracting 23% year over year — slower than 73% of Healthcare companies we track, at a -504.7% net margin.
Peers · Healthcare
Cardiff Oncology, Inc.53DPMGC Holdings Inc.29DGrapefruit USA, Inc.——Ernexa Therapeutics Inc.43DViropro Inc.——VYNE Therapeutics Inc.38DKey facts
CEORoger John Dumoulin-White
SectorHealthcare
IndustryMedical - Devices
HeadquartersToronto, ON
ExchangeOTC: TLTFF
Employees14
IPO date2010-04-05
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.